Cytokine Therapeutics: Current and Future Markets in Inflammatory Disease - Market Research Reports - Research and Markets

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/314808

Cytokine Therapeutics: Current and Future Markets in Inflammatory Disease

Description:

Inflammatory diseases-both chronic diseases, such as rheumatoid arthritis (RA), and acute diseases, such as septic shock-pose a substantial economic burden. Inflammatory diseases affect more than 500 million patients in the major pharmaceutical markets, and total prevalence is growing. In the treatment of these diseases, cytokine therapeutic agents play a major role. The five cytokine agents that have reached the U.S. and European markets so far have achieved major commercial success: in 2004, the value of the global anti-inflammatory cytokines market was $6.5 billion. Cytokine therapeutics may in the future prove useful in the treatment of many other diseases, but owing to the value of the inflammatory disease market and the great interest in developing new cytokine therapeutics to treat inflammatory diseases, this report focuses only on these indications, describing the role of cytokines in inflammation, surveying the current market, discussing emerging agents in detail, and concluding with a comprehensive market outlook.

Business Implications

- By 2004, five products that target cytokines, all recombinant agents, had reached the market; sales of these agents reached $6.5 billion in that year, primarily for treatment of inflammatory diseases such as rheumatoid arthritis (RA) and Crohn's disease (CD). Nearly all sales were generated by the three available anti-TNF-a agents: etanercept, infliximab, and adalimumab.

- Twenty-one recombinant products that target 11 different cytokines are in clinical development for conditions such as RA, psoriasis, CD, asthma, multiple sclerosis, and osteoarthritis. A significant number of orally active, small-molecule inhibitors of cytokine production are also in clinical development for the same diseases. Development of the marketed cytokine therapeutics for additional indications is ongoing.

- The complexity of cytokines and their receptors has so far hindered the development of additional cytokine therapeutics, and we expect
few agents in development to reach the market before 2010. Therefore, currently available cytokine therapeutics will face relatively few challenges from new cytokine therapeutics. However, the existing agents will face competition from drugs that offer alternative approaches to the treatment of inflammatory disease, including the T-cell modulators efalizumab and alefacept and the lymphocyte modulator abatacept.

- Use of the existing cytokine therapeutics in inflammatory indications will grow significantly through 2009, and we expect substantial
growth in sales of this drug class. However, assessment of the market beyond 2009 is difficult owing to the many uncertainties about which of the newer agents will come to market in 2010 and beyond. Nevertheless, we project continuing growth in cytokine therapeutics sales beyond 2010, especially if anti-IL-1 therapy becomes an established treatment for osteoarthritis.

Contents:

Introduction
Treatment of Inflammatory Disease—Overview
The Role of Cytokines in Inflammation
Overview of Current Market
Emerging Therapeutics
Recombinant Agents
Oral Therapeutics
Market Outlook
Therapeutics Emerging Before 201
Impact of Cytokine Therapeutics by Therapeutic Segment
Table 1. Prevalence of Diagnosed Inflammatory Diseases (thousands of cases) in the Seven Major Markets, 2004 and 2009
Table 2. Cytokine Therapeutics Approved or in Development for Inflammatory Diseases
Table 3. 2004 Sales of Anti-TNF-? Products
Table 4. Recombinant Cytokine Therapeutic Agents in Clinical Development, 2005
Table 5. Orally Active Inhibitors of Cytokine Formation in Clinical Development, 2005
Table 6. Oral PDE4 Inhibitors in Clinical Development, 2005
Table 7. Forecasted 2009 Sales of Select Cytokine Therapeutic Agents in the Seven Major Markets, by Indication
Figure 1. Anti-TNF-a Agents: Market Shares, First Quarter 2005
Figure 2. Anti-TNF-a Agents: shares of U.S. Sales for Treatment of Rheumatoid Arthritis, 2004

Companies Mentioned

Companies mentioned in this report include: - Abbott - Aerovance - Altana - Amgen - Biogen Idec - BioWa - Boehringer Ingelheim - Cambridge Antibody Technology - Celgene - Celltech - Centocor - Chugai - Forest - Genmab - GlaxoSmithKline - Glenmark - Kissei - Merck - Neuro3D - Novartis - NPS Pharmaceuticals - Ono - OPi - Otsuka - Pharmacia - Pharmacopeia - Protein Design Labs - Regeneron - Roche - Sanofi-Aventis - Schering-Plough - Scios - Serono - Takeda - Tanabe - Teijin - UCB - Vertex - Wyeth

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/314808

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 14/02/2012 22:02:05

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.


Product Name:
Cytokine Therapeutics: Current and Future Markets in Inflammatory Disease
Web Address:
http://www.researchandmarkets.com/reports/314808
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

	Format	Quantity	Price
	Electronic (PDF) - Single User		€764.00

Contact information
Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed 14/02/2012 22:02:05

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder's Name:

Cardholder's Signature:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)